Welcome to our dedicated page for Walgreens Boots Alliance news (Ticker: WBA), a resource for investors and traders seeking the latest updates and insights on Walgreens Boots Alliance stock.
Walgreens Boots Alliance, Inc. (WBA) is the first global pharmacy-led, health and wellbeing enterprise. Formed in December 2014 through the combination of Walgreens and Alliance Boots, the company harnesses the strengths of two iconic brands with complementary geographic footprints and a heritage that dates back over a century. WBA operates over 13,100 stores in 11 countries and has a presence in more than 25 countries, employing over 370,000 people worldwide.
WBA is the largest retail pharmacy, health, and daily living destination in the USA and Europe, with its extensive network ensuring nearly three-quarters of Americans live within five miles of a Walgreens location. The company's revenue is majorly generated from prescription drug sales, which account for about two-thirds of its overall sales. Walgreens alone contributes to 20% of total prescription revenue in the U.S.
Alongside prescription sales, WBA's operations include retail products, European drug wholesale, and healthcare services. The company is continuously expanding its services with initiatives such as Health Corner and Village Medical, aiming to create an omnichannel experience for patients and positioning itself as a one-stop healthcare provider.
In recent developments, WBA has made significant strides towards sustainability, such as reducing single-use plastic in its packaging and collaborating with industry partners for better recycling practices. The efforts are part of the company's broader Environmental, Social, and Governance (ESG) initiatives aimed at reducing its environmental impact.
Additionally, Walgreens is expanding its specialty pharmacy services through the introduction of Walgreens Specialty Pharmacy, which integrates AllianceRx and focuses on providing care for patients with complex, chronic conditions. This initiative aims to improve patient outcomes and provide greater value to payers and partners.
WBA’s specialty pharmacy business is bolstered by its subsidiary, Shields Health Solutions, which supports health systems' specialty pharmacies across the U.S. Through these efforts, Walgreens continues to play a pivotal role in the healthcare system, offering comprehensive solutions that bridge gaps in patient care.
For National Women's Health Month, Walgreens has been highlighting the contributions of its female leaders, emphasizing the importance of women's health and wellness. The company organized events focused on work-life balance, mental health, and leadership development, furthering its commitment to diversity, equity, and inclusion.
With a mission to provide joy through better health, Walgreens Boots Alliance remains a trusted name in the healthcare and retail pharmacy sectors, continuously evolving to meet the needs of its customers and communities worldwide.
Walgreens Boots Alliance (WBA) has appointed Bryan C. Hanson to its board of directors, effective October 27, 2022. With over 30 years in healthcare and technology, Hanson brings significant expertise to the company, serving on both the compensation and leadership performance committee and the finance and technology committee. Currently, he is the president and CEO of Zimmer Biomet. WBA's executive chairman, Stefano Pessina, and CEO Roz Brewer expressed optimism about his contribution to WBA's consumer-centric healthcare strategy.
Walgreens Boots Alliance (WBA) has declared a quarterly dividend of 48 cents per share, unchanged from the previous quarter and representing a 0.5% increase from the same quarter last year. The payment date is set for December 12, 2022, with record date November 15, 2022. This marks the company's 360th consecutive quarter of dividend payments and 47 years of raised dividends, showcasing its long-standing commitment to shareholder returns.
Walgreens Boots Alliance (WBA) announced that CEO Roz Brewer and CFO James Kehoe will present at the Credit Suisse 31st Annual Healthcare Conference on November 9, 2022, at 11:00 a.m. Pacific time in Rancho Palos Verdes, California. The presentation will be available via a live webcast on the WBA investor relations website. WBA, a leader in integrated healthcare and retail pharmacy, operates approximately 13,000 locations globally and is committed to improving health services and community well-being.
Walgreens has announced a significant update to its retail pharmacy operations, removing task-based metrics from performance reviews for its 24,000+ pharmacists. This initiative aims to enhance patient care and experiences by allowing pharmacists to focus on clinical services rather than administrative tasks. The company has invested over
Walgreens launched the 2022-2023 Flu Index to track flu activity, showing it is over 10 times higher compared to last season and has doubled in the last two weeks. This initiative aims to encourage flu vaccinations amid rising flu cases across the United States. Notably, Louisiana, Texas, and Mississippi have reported the highest flu activity. The CDC recommends flu shots for everyone aged 6 months and older, especially before the holiday season.
Walgreens Boots Alliance (WBA) reported its fourth quarter and fiscal year results for 2022, highlighting a loss per share of $0.48, a decline from earnings of $0.41 in the prior year. Adjusted EPS fell by 31.8% to $0.80. Sales for the fourth quarter totaled $32.4 billion, down 5.3% year-over-year. Despite challenges, WBA raised its long-term U.S. Healthcare sales target to $11-$12 billion by fiscal year 2025, predicting low-teens adjusted EPS growth. The company's management expressed confidence in its strategic transformation towards becoming a consumer-centric healthcare leader.
Walgreens announces the availability of updated COVID-19 boosters, authorized by the FDA and recommended by the CDC, for individuals aged 5 and older at select locations. The boosters provide enhanced protection against COVID-19 variants, including Omicron BA.4 and BA.5. Parents are encouraged to schedule appointments for their children online or via the Walgreens app. With rising COVID-19 cases in the UK, Walgreens emphasizes vaccination as a critical preventive measure. The company has administered over 70 million COVID-19 vaccinations and is noted as the largest pediatric vaccine provider among retail pharmacies.
Walgreens Boots Alliance (WBA) has announced its plan to fully acquire CareCentrix for approximately $392 million, enhancing its presence in the $75 billion homecare sector. This acquisition follows WBA's previous 55% investment in CareCentrix in August 2022. The deal is expected to close by March 2023, subject to customary conditions. CareCentrix manages care for over 19 million members and generated pro forma sales of $1.5 billion in fiscal year 2021. The move aligns with WBA's strategy to transform into a consumer-centric healthcare company.
Walgreens has partnered with Lexie Hearing to offer Lexie Lumen hearing aids over-the-counter at Walgreens stores nationwide starting October 17. This initiative is a response to the OTC Hearing Aid Act, allowing consumers to buy hearing aids without a prescription. Priced at $799 or as low as $39 per month, the hearing aids come with a complete solution including batteries and a 45-day money-back guarantee. The collaboration aims to make affordable hearing aids more accessible to the approximately 37.5 million Americans with hearing difficulties.
FAQ
What is the current stock price of Walgreens Boots Alliance (WBA)?
What is the market cap of Walgreens Boots Alliance (WBA)?
What is Walgreens Boots Alliance, Inc. (WBA)?
How many stores does Walgreens Boots Alliance operate?
What are the main revenue sources for Walgreens Boots Alliance?
What recent sustainability efforts has WBA made?
What is Walgreens Specialty Pharmacy?
How does Walgreens Boots Alliance contribute to women's health?
What role does Shields Health Solutions play within WBA?
How does Walgreens Boots Alliance ensure accessibility for its customers?
What is WBA's mission?
What recent expansions has WBA made in its core pharmacy business?
